MktsMarkets

Outlook Therapeutics, Inc.
NASDAQ: OTLKKey statistics
OTLK News
Stories mentioning OTLK from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1,505 | |||||||
| Cost of Goods Sold | 149.00 | 30.00 | 440.00 | |||||
| Gross Profit | (22.00) | (1,237) | (1,009) | 1,066 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 4,501 | 3,634 | 5,979 | 7,135 | 4,407 | 9,660 | 12,523 | 11,202 |
| Sales General & Admin | 9,505 | 8,612 | 10,327 | 9,679 | 7,985 | 11,947 | 8,361 | |
| Total Operating Expenses | 19,563 | |||||||
| Operating Income (Loss) | (14,027) | (13,484) | (17,314) | (15,749) | (12,392) | (21,607) | (22,877) | (19,563) |
| Interest Income | 405.00 | |||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (4,453) | (20,153) | (46,354) | 44,409 | ||||
| Tax Provision | 3.00 | |||||||
| Net Income (Loss) | (4,453) | (23,058) | (13,293) | (20,153) | (46,357) | 17,378 | 5,691 | 44,409 |
| Earnings Per Share (Basic) | (0.05) | (0.38) | (0.38) | (0.55) | (1.50) | 0.72 | 0.31 | 1.91 |
| Earnings Per Share (Diluted) | (0.05) | (0.38) | (0.38) | (0.55) | (1.50) | 0.72 | 0.31 | (0.89) |
| Weighted Average Shares Outstanding (Basic) | 81,836 | 60,205 | 34,796 | 36,957 | 30,874 | 24,234 | 18,549 | 23,227 |
| Weighted Average Shares Outstanding (Diluted) | 81,836 | 60,205 | 34,796 | 36,957 | 30,874 | 24,234 | 18,549 | 25,476 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About OTLK
Outlook Therapeutics, Inc. (NASDAQ: OTLK) is a stock listed on the Nasdaq Stock Market under the ticker symbol OTLK. It last traded at $0.4100 (Nov 13, 2026, 9:30 AM ET), down 6.1% on the day. That gives Outlook Therapeutics a market capitalisation of $106.2M.
Over the past 52 weeks OTLK has traded between $0.1600 and $2.54.
For the quarter ended Mar 31, 2026 it reported a net loss of $4.5M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | — | -$4.5M | — |
| Dec 31, 2025 | — | -$23.1M | — |
| Sep 30, 2025 | — | -$13.3M | — |
| Jun 30, 2025 | $1.5M | -$20.2M | -1339.1% |
From Outlook Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…